Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease therapy Leqembi, with a narrower label than originally proposed.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,